Profile data is unavailable for this security.
About the company
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
- Revenue in USD (TTM)15.45m
- Net income in USD-111.57m
- Incorporated2020
- Employees52.00
- LocationTaysha Gene Therapies Inc3000 Pegasus Park Drive, Suite 1430DALLAS 75247United StatesUSA
- Phone+1 (214) 612-0000
- Websitehttps://tayshagtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Theravance Biopharma Inc | 57.42m | -55.19m | 466.18m | 99.00 | -- | 2.17 | -- | 8.12 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 469.74m | 127.00 | -- | 5.92 | -- | 93.95 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
Adaptive Biotechnologies Corp | 170.28m | -225.25m | 474.53m | 709.00 | -- | 1.51 | -- | 2.79 | -1.56 | -1.56 | 1.18 | 2.13 | 0.2244 | 5.23 | 4.36 | 240,163.60 | -29.69 | -19.69 | -34.13 | -22.06 | 55.63 | 67.18 | -132.32 | -122.27 | 4.50 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Third Harmonic Bio Inc | 0.00 | -30.82m | 478.80m | 30.00 | -- | 1.75 | -- | -- | -0.9461 | -0.9461 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -10.70 | -- | -10.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
Fate Therapeutics Inc | 63.53m | -160.93m | 480.31m | 181.00 | -- | 1.13 | -- | 7.56 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Fulcrum Therapeutics Inc | 2.81m | -97.34m | 481.69m | 76.00 | -- | 2.04 | -- | 171.73 | -1.59 | -1.59 | 0.0458 | 3.80 | 0.0116 | -- | 1.68 | 36,907.89 | -40.19 | -50.55 | -42.88 | -55.91 | -- | -- | -3,470.05 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
Voyager Therapeutics Inc | 250.01m | 132.33m | 486.23m | 162.00 | 3.02 | 1.67 | 3.56 | 1.94 | 2.96 | 2.96 | 5.56 | 5.37 | 0.9792 | -- | 5.97 | 1,543,259.00 | 51.83 | 0.6378 | 70.85 | 0.8203 | -- | -- | 52.93 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Taysha Gene Therapies Inc | 15.45m | -111.57m | 489.99m | 52.00 | -- | 6.54 | -- | 31.71 | -1.37 | -1.37 | 0.1333 | 0.4008 | 0.1034 | -- | -- | 297,134.60 | -74.62 | -- | -111.87 | -- | -- | -- | -722.06 | -- | -- | -50.05 | 0.3529 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Travere Therapeutics Inc | 145.24m | -376.33m | 498.51m | 380.00 | -- | 2.46 | -- | 3.43 | -4.98 | -1.50 | 1.96 | 2.66 | 0.1988 | 1.40 | 7.68 | 382,205.30 | -51.50 | -36.95 | -65.94 | -44.77 | 92.12 | 95.92 | -259.11 | -165.79 | 3.41 | -- | 0.6526 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
Nkarta Inc | 0.00 | -117.50m | 500.32m | 150.00 | -- | 1.28 | -- | -- | -2.40 | -2.40 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -27.59 | -32.39 | -29.14 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Tscan Therapeutics Inc | 21.05m | -89.22m | 503.40m | 154.00 | -- | 2.79 | -- | 23.92 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
GeneDx Holdings Corp | 221.85m | -135.02m | 510.46m | 1.00k | -- | 2.46 | -- | 2.30 | -5.25 | -5.25 | 8.60 | 7.93 | 0.4721 | 9.16 | 7.27 | 221,849.00 | -28.73 | -- | -35.07 | -- | 50.57 | 11.50 | -60.86 | -121.10 | 2.99 | -130.27 | 0.2015 | -- | -13.69 | 8.72 | 67.98 | -- | 7.77 | -- |
Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 512.17m | 118.00 | -- | 4.74 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
Alector Inc | 97.06m | -130.39m | 512.77m | 244.00 | -- | 3.37 | -- | 5.28 | -1.56 | -1.56 | 1.16 | 1.58 | 0.1377 | -- | 75.04 | 397,795.10 | -18.50 | -20.00 | -22.92 | -23.81 | -- | -- | -134.34 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Allogene Therapeutics Inc | 95.00k | -327.27m | 513.88m | 232.00 | -- | 0.991 | -- | 5,409.23 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 22.44m | 12.00% |
RA Capital Management LPas of 31 Dec 2023 | 18.47m | 9.88% |
RTW Investments LPas of 31 Dec 2023 | 16.89m | 9.03% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 6.16m | 3.29% |
Avoro Capital Advisor LLCas of 31 Dec 2023 | 4.36m | 2.33% |
Baker Bros. Advisors LPas of 31 Dec 2023 | 4.00m | 2.14% |
Eversept Partners LPas of 31 Dec 2023 | 3.78m | 2.02% |
Tybourne Capital Management (HK) Ltd.as of 31 Dec 2023 | 3.70m | 1.98% |
Invus Public Equities Advisors LLCas of 31 Dec 2023 | 3.66m | 1.96% |
Acuta Capital Partners LLCas of 31 Dec 2023 | 3.59m | 1.92% |